SRD5A2 and prostate carcinoma: In addition, immunohistochemistry was conducted to validate the protein expression of key targets in clinical prostate cancer tissues.<h4>Results</h4>Among the 2,610 differentially expressed genes (DEGs) identified, PRKCB and SRD5A2 emerged as key hub genes.